May 6, 2020 / 1:23 PM / 25 days ago

BRIEF-Horizon Therapeutics Reports Qtrly Loss Per Share of $0.07

May 6 (Reuters) - Horizon Therapeutics PLC:

* Q1 SALES ROSE 27 PERCENT TO 355.9 MILLION USD

* INCREASING 2020 NET SALES GUIDANCE FOR TEPEZZA TO GREATER THAN $200 MILLION FROM $30 MILLION TO $40 MILLION

* INCREASING FULL-YEAR 2020 NET SALES GUIDANCE TO $1.40 TO $1.45 BILLION

* REVISING FULL-YEAR 2020 ADJUSTED EBITDA GUIDANCE TO $450 TO $500 MILLION

* QTRLY LOSS PER SHARE $0.07

* QTRLY NON-GAAP EARNINGS PER SHARE $0.40

* Q1 EARNINGS PER SHARE VIEW $0.21, REVENUE VIEW $287.9 MILLION — REFINITIV IBES DATA

* FY2020 REVENUE VIEW $1.35 BILLION — REFINITIV IBES DATA

* UPDATED GUIDANCE ASSUMES THAT HEALTHCARE ACTIVITY BEGINS TO RETURN IN THE SECOND HALF OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below